Atlas Trials

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Clinical trial NCT03013101 · UNKNOWN

Trial details

NCT number
NCT03013101
Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced MelanomaMetastatic Melanoma
Start date
2016-12-28
Primary completion
2018-09-16
Enrollment
128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.